Liquid Biopsy Market by Clinical Application, Scope, Growth, Analysis and Outlook to 2023
ReportsWeb.com published “Liquid Biopsy Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
(EMAILWIRE.COM, January 22, 2018 ) According to Publisher, the Global Liquid Biopsy market is expected to grow from $310.0 million in 2016 to reach $1201.52 million by 2023 with a CAGR of 21.3%. Increasing research & developments and clinical trials for diagnostics, and technological developments are some of the factors driving the market growth. Moreover, growing prevalence of cancer, increasing awareness about liquid biopsy are the factors fostering the market growth. On the other hand, higher costs and complex regulations are restraining the market growth.
For more information http://www.reportsweb.com/liquid-biopsy-global-market-outlook-2017-2023
Liquid biopsy tests are used to help find cancer at an early stage. These tests are performed to interpret the molecular aspects of cancer across the healthcare and research settings, such as research laboratories, physicians, pathological and hospitals. The circulating tumor cells leads the market globally with the largest market share and is expected to grow with a highest CAGR during the forecast period. By cancer type, lung cancer segment is expected to witness high growth rate during the forecast period. North America emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S.
Some of the key players in global liquid biopsy market include Roche Diagnostics, Guardant Health, Inc, Illumina, Inc, Biocept, Inc, Myriad Genetics, Inc, Qiagen N.V. , Genomic Health, Inc
Thermo Fisher Scientific Inc , Bio-Rad Laboratories, Inc, Epic Sciences, Exosome, Cynvenio
Guardant Health, Personal Genome Diagnostics and Janssen Diagnostics, LLC.
Clinical Applications Covered:
-Treatment Monitoring
-Recurrence Monitoring
-Early Cancer Screening
-Therapy Selection
Product and Services Covered:
-Platforms & Instruments
-Assay Kits & Reagents
-Services
Cancer Types Covered:
-Breast Cancer
-Liver Cancer
-Lung Cancer
-Colorectal Cancer
-Prostate Cancer
-Other Cancer Types
Request Sample Copy http://www.reportsweb.com/inquiry&RW00011415606/sample
Circulating Biomarkers Covered:
-Circulating Tumor DNA (CTDNA)
-Extracellular Vesicles (Evs)
-Circulating Tumor Cells
-Cell-Free DNA
-Exosomes
-Other Circulating Biomarkers
Sample Types Covered:
-Urine
-Blood
-Other Sample Types
End Users Covered:
-Academic and Research Centers
-Hospitals and Physician Laboratories
-Diagnostic centres & Reference Laboratories
Regions Covered:
-North America
-US
-Canada
-Mexico
-Europe
-Germany
-UK
-Italy
-France
-Spain
-Rest of Europe
-Asia Pacific
-Japan
-China
-India
-Australia
-New Zealand
-South Korea
-Rest of Asia Pacific
-South America
-Argentina
-Brazil
-Chile
-Rest of South America
-Middle East & Africa
-Saudi Arabia
-UAE
-Qatar
-South Africa
-Rest of Middle East & Africa
Make an enquiry: http://www.reportsweb.com/inquiry&RW00011415606/buying
For more information http://www.reportsweb.com/liquid-biopsy-global-market-outlook-2017-2023
Liquid biopsy tests are used to help find cancer at an early stage. These tests are performed to interpret the molecular aspects of cancer across the healthcare and research settings, such as research laboratories, physicians, pathological and hospitals. The circulating tumor cells leads the market globally with the largest market share and is expected to grow with a highest CAGR during the forecast period. By cancer type, lung cancer segment is expected to witness high growth rate during the forecast period. North America emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S.
Some of the key players in global liquid biopsy market include Roche Diagnostics, Guardant Health, Inc, Illumina, Inc, Biocept, Inc, Myriad Genetics, Inc, Qiagen N.V. , Genomic Health, Inc
Thermo Fisher Scientific Inc , Bio-Rad Laboratories, Inc, Epic Sciences, Exosome, Cynvenio
Guardant Health, Personal Genome Diagnostics and Janssen Diagnostics, LLC.
Clinical Applications Covered:
-Treatment Monitoring
-Recurrence Monitoring
-Early Cancer Screening
-Therapy Selection
Product and Services Covered:
-Platforms & Instruments
-Assay Kits & Reagents
-Services
Cancer Types Covered:
-Breast Cancer
-Liver Cancer
-Lung Cancer
-Colorectal Cancer
-Prostate Cancer
-Other Cancer Types
Request Sample Copy http://www.reportsweb.com/inquiry&RW00011415606/sample
Circulating Biomarkers Covered:
-Circulating Tumor DNA (CTDNA)
-Extracellular Vesicles (Evs)
-Circulating Tumor Cells
-Cell-Free DNA
-Exosomes
-Other Circulating Biomarkers
Sample Types Covered:
-Urine
-Blood
-Other Sample Types
End Users Covered:
-Academic and Research Centers
-Hospitals and Physician Laboratories
-Diagnostic centres & Reference Laboratories
Regions Covered:
-North America
-US
-Canada
-Mexico
-Europe
-Germany
-UK
-Italy
-France
-Spain
-Rest of Europe
-Asia Pacific
-Japan
-China
-India
-Australia
-New Zealand
-South Korea
-Rest of Asia Pacific
-South America
-Argentina
-Brazil
-Chile
-Rest of South America
-Middle East & Africa
-Saudi Arabia
-UAE
-Qatar
-South Africa
-Rest of Middle East & Africa
Make an enquiry: http://www.reportsweb.com/inquiry&RW00011415606/buying
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results